Clinical correlates of circulating cell-free DNA tumor fraction.
<h4>Background</h4>Oncology applications of cell-free DNA analysis are often limited by the amount of circulating tumor DNA and the fraction of cell-free DNA derived from tumor cells in a blood sample. This circulating tumor fraction varies widely between individuals and cancer types. Cl...
Guardado en:
Autores principales: | Joerg Bredno, Jafi Lipson, Oliver Venn, Alexander M Aravanis, Arash Jamshidi |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fc02433213244ffc9d82bfb80a55e61d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA burden
por: Guanhua Zhu, et al.
Publicado: (2021) -
Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma
por: S. Manier, et al.
Publicado: (2018) -
A novel method for liquid-phase extraction of cell-free DNA for detection of circulating tumor DNA
por: Filip Janku, et al.
Publicado: (2021) -
Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers
por: Hitomi Sumiyoshi Okuma, et al.
Publicado: (2021) -
Abnormal Circulating Maternal miRNA Expression Is Associated with a Low (<4%) Cell-Free DNA Fetal Fraction
por: Graziano Santoro, et al.
Publicado: (2021)